

Figure S1 Median time from the beginning of maintenance in four groups. I, immune-checkpoint inhibitors; C, chemotherapy; A, anti-angiogenesis drugs.




Figure S2 Forest plot HR in PFS of I+A maintenance versus I maintenance and I+A maintenance versus I+A±C in different subgroups. ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death-ligand 1; HR, hazard ratio; CI, confidence interval; I, immune-checkpoint inhibitors; C, chemotherapy; A, anti-angiogenesis drugs; NA, not available; PFS, progression-free survival.




Figure S3 Progression-free survival in four groups, based on PD-L1 expression. (A) PD-L1 <1%; (B) PD-L1 $\geq 1\%$; (C) PD-L1 <50%; (D) PD-L1 $\geq 50\%$. I, immune-checkpoint inhibitors; C, chemotherapy; A, anti-angiogenesis drugs; PD-L1, programmed cell death-ligand 1.




Figure S4 Schematic diagram of chemo-holiday regimen. ICIs, immune checkpoint inhibitors; PD, progressive disease.